Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica by Yanai, Hidekatsu et al.
© 2009 Yanai et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging
Clinical Interventions in Aging 2009:4 391–395 391
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R I g I n A L   R e s e A R C h
Clinical, radiological, and biochemical 
characteristics in patients with diseases 
mimicking polymyalgia rheumatica
hidekatsu Yanai1,2 
hiroshi Yoshida2,3 
norio Tada1,2
1Division of general Medicine, 
Department of Internal Medicine,  
The Jikei University school of 
Medicine, Kashiwa, Japan; 2Institute 
of Clinical Medicine and Research, 
the Jikei University school of 
Medicine, Chiba, Japan; 3Department 
of Laboratory Medicine, The Jikei 
University school of Medicine, 
Kashiwa, Japan
Correspondence: hidekatsu Yanai 
Division of general Medicine, 
Department of Internal Medicine,  
The Jikei University school of Medicine, 
Kashiwa, Japan 
Tel +81 4 7164 1111 
Fax +81 4 7164 1126 
email yanaih@jikei.ac.jp
Abstract: To find out clues to differentiate between polymyalgia rheumatica (PMR) and other 
diseases that mimic PMR. We studied Japanese patients with PMR (n = 7), pseudogout (n = 1), 
remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome (n = 1), and 
post-infectious polyarthritis (n = 1). The distribution of inflammation in patients was evaluated 
using a gallium-67 scintigraphy. We measured serum C-reactive protein (CRP), matrix metal-
loproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF) in patients before and 
after treatment. Further, we compared the clinical course of PMR with that of other diseases that 
mimic PMR. Patients with pseudogout, RS3PE syndrome, post-infectious polyarthritis mani-
fested similar changes in scintigraphic findings and serum CRP, MMP-3, and VEGF levels to 
PMR before the treatment. A significant reduction in serum CRP levels at one week after use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) is a good clue to differentiate pseudogout and 
post-infectious polyarthritis from PMR. Chondrocalcinosis in the radiographs of joints is also 
effective to differentiate pseudogout from PMR. A small reduction of CRP levels after NSAIDs 
use and promptly ameliorated CRP and symptoms by a low-dose steroid therapy, which was 
commonly observed in patients with PMR, were also found in a patient with RS3PE syndrome. 
Pitting edema of the back of hands and gallium uptake in metacarpophalangeal (MCP) joints 
were useful to differentiate RS3PE syndrome from PMR. In conclusion, pseudogout, RS3PE 
syndrome, post-infectious polyarthritis should be included in the spectrum of diseases mimicking 
PMR. A promptly decreased serum CRP level by NSAIDs is a good clue to differentiate 
pseudogout and post-infectious polyarthritis from PMR. Pitting edema of the back of hands and 
symmetric gallium uptake in MCP joints are characteristic for RS3PE syndrome.
Keywords: gallium-67 scintigraphy, polymyalgia rheumatica, pseudogout, post-infectious 
polyarthritis, RS3PE syndrome
Introduction
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease in elderly people. 
It is a common indication for a long term treatment with steroid in patients based in the 
community. Although the cause of PMR is largely unknown, the presence of articular 
synovitis in PMR has been proven by synovial biopsy.1 Recently, we have reported 
that symmetrical gallium-67 uptake in the shoulders and elevated serum matrix metal-
loproteinase-3 (MMP-3) and vascular endothelial growth factor (VEGF) levels as the 
markers for synovitis in patients with PMR.2 Although bilateral aching and stiffness 
of shoulders and pelvic girdle of acute or subacute onset are very characteristic for 
PMR, several other diseases can be present with similar symptoms. Here, we studied 
a gallium scintigraphic findings, and serum C-reactive protein (CRP), MMP-3 and Clinical Interventions in Aging 2009:4 392
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VEGF levels in patients with diseases that mimic PMR. 
Further, we discuss clues to differentiate between PMR and 
other diseases that mimic PMR.
Methods
We studied Japanese patients with PMR (n = 7), pseudogout 
(n = 1), remitting seronegative symmetrical synovitis with 
pitting edema (RS3PE) syndrome (n = 1), and post-infectious 
polyarthritis (n = 1). Diagnosis for PMR had been done using 
the Hunder’s criteria.3 The distribution of inflammation in 
patients was evaluated using a gallium-67 scintigraphy whole 
body scan before the treatment. We measured serum CRP, 
MMP-3, and  VEGF levels as the markers for a synovial 
inflammation before and after the treatment.4,5 Serum CRP and 
MMP-3 concentrations were measured by polyclonal antibody-
based (Dade Behring, Marburg, Germany) and monoclonal 
antibody-based (Daiichi Fine Chemical, Co., Ltd., Toyama, 
Japan) latex agglutination method, respectively. Serum con-
centrations of  VEGF165 (major form of  VEGF) were analyzed 
by enzyme linked immunosorbent assay (ELISA; VEGF165, 
R&D Systems, Inc, Minneapolis, MN, USA).
Results
Patients with PMR
Case P is a 64-year-old woman with PMR (Figure 1P). 
Symmetrical and bilateral gallium uptake in shoulders, pelvic 
girdle, and knees were observed. Age of all patients with 
PMR were over 50 years (Table 1). Serum CRP (normal 
range, 0.3 mg/dL), MMP-3 (normal range, 115 ng/ml), 
and VEGF (normal range, 17.3–59.7 pg/ml) levels were 
significantly elevated in patients with PMR before the treat-
ment (Table 1). Rheumatic factor (RF), antinuclear antibody 
(ANA), myeloperoxidase-antineutrophil cytoplasmic 
antibody (MPO-ANCA), and proteinase-3 (PR3)-ANCA 
were negative in all PMR patients. Daily administration of 
20 mg corticosteroid ameliorated symptoms and significantly 
decreased serum CRP and VEGF levels (Table 1). Although a 
statistically significant difference between values before and 
after the treatment was not observed, corticosteroid increased 
serum MMP-3 levels. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) did not ameliorate patients’ symptoms and serum 
CRP levels (Table 2).
Case A
An 83-year-old man was admitted via emergency room com-
plaining of fever and polyarthralgia, including bilateral wrists, 
knees, and hip joints. His body temperature was 38.1 °C. 
Physical examination showed swelling of wrists, knees, and 
hip joints. Laboratory evaluation on admission was notable 
for a CRP level of 24.3 mg/dl, and RF, ANA, MPO-ANCA, 
and PR3-ANCA were negative. Serum MMP-3 and VEGF 
levels were elevated before the treatment (Table 1). His 
clinical and biochemical characteristics, and symmetrical and 
bilateral gallium uptake in shoulders, pelvic girdle, knees, 
and ankles, suggested the presence of PMR (Figure 1A). 
However, the radiographs of the wrist (Figure 2A), knee 
(Figure 2B), and hip (Figure 2C) showed chondrocalcinosis. 
A P
Figure 1 Gallium-67 scintigraphic findings of patients with polymyalgia rheumatica 
(P), pseudogout A), remitting seronegative symmetrical synovitis with pitting edema 
(Rs3Pe) syndrome B), and post-infectious polyarthritis C). A–C corresponds to case 
A–C in Table 1, respectively. Arrows indicate a gallium uptake. Dotted arrows indicate 
a gallium uptake in metacarpophalangeal joints in a patient in Rs3Pe syndrome.
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and VEGF levels were significantly elevated (Table 1), and 
RF, ANA, MPO-ANCA, and PR3-ANCA were negative. 
He was finally diagnosed as having RS3PE syndrome. 
NSAIDs did not ameliorate patient’s symptoms and serum 
CRP, however, a low dose of steroid (daily use of 20 mg 
prednisolone) was very effective in relieving his symptoms 
and decreasing serum CRP level. Pitting edema on the back 
of hands and symmetric gallium uptake in MCP joints are 
characteristic for RS3PE syndrome.
Case C
An 89-year-old woman was admitted to the department of 
ophthalmology due to left intraocular inflammation, and her left 
eyeball was extracted. At the fourth day after eyeball extraction, 
she had fever (39.2 °C), and her serum CRP level was elevated 
(14.5 mg/dl). Antibiotic therapy was started, but, antibiotic 
did not decrease her body temperature and serum CRP level 
(12.1 mg/dl at the fifth day after the beginning of antibiotic 
therapy), and she was referred and admitted to our department. 
She complained of fever and polyarthralgia. Serum RF, ANA, 
Arthrocentesis on the right knee was performed. Calcium 
pyrophosphate dihydrate crystals were detected in the joint 
fluid, suggesting that this patient was having pseudogout. 
Loxoprofen (180 mg/day), NSAIDs, promptly ameliorated 
his symptoms and decreased serum CRP level (1.2 mg/dl at 
seven days after the treatment started) (Table 2), and also 
decreased serum MMP-3 and VEGF levels.
Case B
A 65-year-old man was diagnosed as having deep venous 
thrombosis (DVT) because of edema and pain in lower 
extremities by a family physician, and was referred to the 
department of cardiology. The cardiologist found no evidence 
of DVT and elevated serum CRP level, and then this patient 
was referred and admitted to our department. He complained 
of fever, polyarthralgia, and pitting edema in bilateral hands 
and legs. A gallium-67 scintigraphy revealed symmetrical 
uptake in shoulders, elbows, wrists, pelvic girdle, knees, 
and ankles (Figure 1B). In contrast to PMR, a symmetrical 
gallium uptake in MCP joints was observed. Serum MMP-3 
Table 1 Age, serum CRP, MMP-3, VegF levels before and after the treatment in patients with PMR, pseudogout, Rs3Pe syndrome, and 
post-infectious polyarthritis
Case Diagnosis Age CRP (mg/dl) MMP-3 (ng/ml) VEGF (pg/ml)
PMR (n = 7) 78.1 ± 8.2 Before 
After
11.4 ± 4.8 
1.5 ± 1.0*
189.0 ± 91.4 
286.9 ± 204.0
1,114.2 ± 297.4
565.1 ± 182.3*
A Pseudogout 83 Before 
After
24.3
1.2
252.0
117.0
1,190
894
B Rs3Pe syndrome 65 Before 
After
17.8
8.5
729.0
328.0
1,650
1070
C Post-infectious polyarthritis 89 Before 
After
12.1
1.3
238.0
70.1
805
450
Notes: Cases A–C corresponds to A–C in Figure 1, respectively. Values in PMR patients indicate mean ± sD. *P  0.05 vs values before the treatment by Wilcoxon's signed 
rank test. normal range of CRP, MMP-3, and VegF levels is 0.3 mg/dl, 115 ng/ml, and 17.3–59.7 pg/ml, respectively.
Abbreviations: CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; PMR, polymyalgia rheumatica; Rs3Pe, remitting seronegative symmetrical synovitis with pitting 
edema.
Table 2 Changes in serum CRP levels after one week’s treatment using nsAIDs in patients with PMR, pseudogout, Rs3Pe syndrome, 
and post-infectious polyarthritis
Case Diagnosis CRP (mg/dl) %Changes of serum CRP levels
PMR (n = 7) Before  
After one week
10.4 ± 4.4  
9.1 ± 3.4#
−7.2%
A Pseudogout Before  
After one week
24.3  
1.2
−95.1%
B Rs3Pe syndrome Before  
After one week
20.8  
16.2
−22.1%
C Post-infectious polyarthritis Before  
After one week
12.1  
1.3
−89.3%
Notes: Case A–C corresponds to A–C in Figure 1, respectively. Values in PMR patients indicate mean ± sD. #Indicates no significant differences vs values before treatment by 
Wilcoxon’s signed rank test.
Abbreviations: CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; PMR, polymya rheumatica; Rs3Pe, remitting seronegative symmetrical synovitis with pitting 
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MPO-ANCA, and PR3-ANCA were negative. Symmetrical 
gallium uptake in shoulders, elbows, wrists, knees, and ankles 
in a gallium-67 scintigraphy (Figure 1C) and elevated serum 
MMP-3 and VEGF levels (Table 1) suggested the presence 
of PMR. We stopped use of antibiotics and started to use 
loxoprofen (60–120 mg/day), NSAIDs. Loxoprofen promptly 
ameliorated her symptoms and decreased serum CRP level 
(1.3 mg/dl at the seventh day after the treatment started). Her 
clinical course suggested that she was having post-infectious 
polyarthritis due to intraocular inflammation.
Discussion
PMR is a common disease in the elderly. In the United Kingdom, 
age-adjusted incidence of diagnosed PMR was reported to 
have increased by 35% between 1990 and 2001.6 However, 
it is not clear whether this suggests a true increase, increased 
recognition, or overdiagnosis of PMR. There is considerable 
uncertainty related to diagnosis in patients with PMR.7
Recently, developing classification criteria for PMR 
has been reported.8 Most survey respondents agreed 
on the importance of seven core criteria. These were 
1) age  50 years, 2) duration 2 weeks, 3) bilateral 
shoulder and/or pelvic girdle aching, 4) duration of morning 
stiffness 45 min, 5) elevated erythrocyte sedimentation 
rate, 6) elevated CRP, and 7) rapid steroid response. All other 
core criteria except rapid steroid response were observed in 
patients with pseudogout and post-infectious polyarthritis, 
and all core criteria were observed in a patient with RS3PE 
syndrome, suggesting that this newly developed classification 
cannot distinguish pseudogout, post-infectious polyarthritis, 
and RS3PE syndrome from PMR.
Clinical and biochemical characteristics for PMR that we 
newly found were shown in Table 3. Patients with pseudogout, 
RS3PE syndrome, post-infectious polyarthritis manifested similar 
changes in scintigraphic findings and serum CRP, MMP-3, and 
VEGF to PMR. A good response to NSAIDs is an effective clue 
to differentiate pseudogout and post-infectious polyarthritis from 
PMR.9,10 An abnormality (chondrocalcinosis) in the radiographs 
of joints is also effective to differentiate pseudogout from PMR. 
Serum CRP level (24.3 mg/dl) in our patient (Case A) with 
pseudogout was quite high. A Korean female patient of calcium 
pyrophosphate dihydrate crystal deposition disease (CPDD) 
presenting as an acute polyarthritis also showed significantly 
elevated serum CRP levels (18.8 mg/dl).11 However, it is too 
difficult to differentiate CPDD and CPDD + PMR from PMR, 
especially in elderly patients.12 Therefore, we cannot completely 
deny a possible existence of an additional inflammatory 
condition including PMR in Case A.
Figure 2 The radiographs of the patient with pseudogout demonstrated 
chondrocalcinosis (arrows) on the wrist A), knee B), and hip C).
A
B
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A significant difference in gallium scintigraphic findings 
in RS3PE syndrome as compared with PMR was the presence 
of gallium uptake in both MCP joints. However, symmetrical 
gallium uptake was observed in shoulders and pelvic girdle, 
showing the similar scintigraphic findings to PMR. RS3PE 
syndrome is a very rare inflammatory arthritis.13 The features 
of this syndrome are bilateral pitting edema of both hands, 
sudden onset of polyarthritis, age  50 years old, seronega-
tive for RF.14 Mild to moderate synovitis of the joints and 
an association of VEGF with the pathogenesis have been 
observed in RS3PE syndrome as well as PMR.5,15,16 Elevated 
serum CRP, MMP-3 and VEGF levels, a bad response to 
NSAIDs, and rapid steroid response, were observed in 
our patient with RS3PE syndrome as well as patients with 
PMR. Pitting edema of the back of hands and symmetric 
gallium uptake in MCP joints are characteristic for RS3PE 
syndrome. As neoplasm are common in RS3PE syndrome, 
but not in PMR. Follow-up evaluation has been suggested 
to be necessary to observe for the possible occurrence of 
associated neoplasms.17
In  conclusion,  pseudogout,  RS3PE  syndrome, 
post-infectious polyarthritis should be included in the 
spectrum of diseases mimicking PMR. A good response to 
NSAIDs is a good clue to differentiate pseudogout and post-
infectious polyarthritis from PMR. Pitting edema of the back 
of hands and symmetric gallium uptake in MCP joints are 
characteristic for RS3PE syndrome.
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Table 3 Clinical and biochemical characteristics for polymyalgia 
rheumatic
Age  50 years
elevated serum CRP, MMP-3, and VegF levels
symmetrical gallium-67 uptake in shoulders and/or pelvic girdle
A bad response to nsAIDs
A rapid response to steroid
no abnormalities in the radiographs of joints
Abbreviations: CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; nsAIDs, 
nonsteroidal anti-inflammatory drugs.
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